Utente:BilloK/Sandbox: differenze tra le versioni

Contenuto cancellato Contenuto aggiunto
BilloK (discussione | contributi)
Nessun oggetto della modifica
BilloK (discussione | contributi)
Nessun oggetto della modifica
Riga 38:
L'angiotensina III ha il 40% dell'azione vasocostrittoria della II, ma il 100% della sua attività di produzione dell'aldosterone.
 
===AngiotensinAngiotensina IV===
Arg | '''Val-Tyr-Ile-His-Pro-Phe'''
 
Riga 60:
L'angiotensina II agisce sulla corteccia del [[surrene]] stimolando il rilascio di [[aldosterone]], un ormone che causa a livello renale ritenzione di sodio ed eliminazione di potassio. Elevati livelli di angiotensina II sono responsabili degli ugualmente elevati livelli di aldosterone presenti durante la fase luteale del [[ciclo mestruale]].
 
===RenalEffetti effectsrenali===
 
 
Riga 67:
Quest'ormone causa inoltre il rilascio locale di [[prostaglandine]], che invece lavorano come antagonisti della vasocostrizione renale: l'effetto netto di questi meccanismi competitivi risulta in un accurato controllo della filtrazione, e possono variare sotto regime farmacologico.
 
==Voci correlate==
{|class="wikitable"
 
* [[ACE inibitore]]
|+ Renal effects of Angiotensin II
* [[Aldosterone]]
* [[Sistema renina-angiotensina-aldosterone]]
 
==Note==
|-
 
!Target
 
!Action
 
!Mechanism<ref name=boron771> Unless else specified in table, then ref is: {{cite book |author=Walter F., PhD. Boron |title=Medical Physiology: A Cellular And Molecular Approaoch |publisher=Elsevier/Saunders |___location= |year= 2005|pages= |isbn=1-4160-2328-3 |oclc= |doi=}} Page 771 </ref>
 
|-
 
![[Renal artery]] & <BR> [[afferent arterioles]]
 
| [[vasoconstriction]] || [[Voltage-dependent calcium channel|VDCC]]s → [[calcium|Ca<sup>2+</sup>]] influx
 
|-
 
! [[efferent arteriole]]
 
| [[vasoconstriction]] || (probably) activate [[Angiotensin receptor#AT1|Angiotensin receptor 1]] → Activation of [[gq alpha subunit|G<sub>q</sub>]] → ↑[[phospholipase C|PLC]] activity → ↑[[Inositol triphosphate|IP<sub>3</sub>]] and [[diacylglycerol|DAG]] → activation of [[Inositol triphosphate receptor|IP<sub>3</sub> receptor]] in [[sarcoplasmic reticulum|SR]] → ↑intracellular Ca<sup>2+</sup>
 
|-
 
![[mesangial cell]]s
 
| contraction → ↓filtration area ||
 
* activation of [[gq alpha subunit|G<sub>q</sub>]] → ↑[[phospholipase C|PLC]] activity → ↑[[Inositol triphosphate|IP<sub>3</sub>]] and [[diacylglycerol|DAG]] → activation of [[Inositol triphosphate receptor|IP<sub>3</sub> receptor]] in [[sarcoplasmic reticulum|SR]] → ↑intracellular Ca<sup>2+</sup>
 
*[[Voltage-dependent calcium channel|VDCC]]s → [[calcium|Ca<sup>2+</sup>]] influx
 
|-
 
! [[Tubuloglomerular feedback]]
 
| Increased sensitivity || Increase in [[afferent arteriole]] responsiveness to signals from [[macula densa]]
 
|-
 
! [[renal medulla|medullary]] blood flow
 
| Reduction ||
 
|-
 
|}
 
==See also==
 
* [[ACE inhibitor]]
 
* [[Angiotensin receptor]]
 
* [[Angiotensin II receptor antagonist]]
 
* [[Captopril]]
 
* [[Peptides]]
 
==References==
 
{{reflist}}
 
==Further readingBiblografia==
 
*{{En}}{{cite journal | author=de Gasparo M, Catt KJ, Inagami T, "et al." |title=International union of pharmacology. XXIII. The angiotensin II receptors |journal=Parmacol Rev. |volume=52 |pages=415–472 |year=2000 |pmid=10977869 | issue=3}}
{{refbegin | 2}}
 
*{{En}}''Brenner & Rector's The Kidney'', 7th ed., Saunders, 2004.
*{{cite journal | author=de Gasparo M, Catt KJ, Inagami T, "et al." |title=International union of pharmacology. XXIII. The angiotensin II receptors |journal=Parmacol Rev. |volume=52 |pages=415–472 |year=2000 |pmid=10977869 | issue=3}}
 
*{{En}}''Brenner & RectorMosby's TheMedical KidneyDictionary'', 7th3rd edEd., SaundersCV Mosby Company, 20041990.
 
*{{En}}''Mosby'sReview of Medical DictionaryPhysiology'', 3rd20th Ed., CVWilliam MosbyF. Ganong, CompanyMcGraw-Hill, 19902001.
 
*{{En}}''ReviewClinical Physiology of MedicalAcid-Base Physiologyand Electrolyte Disorders'', 20th5th Eded., WilliamBurton FDavid Rose & Theodore W. Ganong,Post McGraw-Hill, 2001.
 
==Collegamenti esterni==
*''Clinical Physiology of Acid-Base and Electrolyte Disorders'', 5th ed., Burton David Rose & Theodore W. Post McGraw-Hill, 2001
 
* http://www.my-personaltrainer.it/fisiologia/renina-angiotensina.html
{{PBB_Further_reading
 
{{portale|biologia|medicina}}
| citations =
 
[[Categoria:Ormoni]]
*{{cite journal | author=Lees KR, MacFadyen RJ, Doig JK, Reid JL |title=Role of angiotensin in the extravascular system |journal=Journal of human hypertension |volume=7 Suppl 2 |issue= |pages= S7–12 |year= 1993 |pmid= 8230088 |doi= }}
 
[[Categoria:Proteine]]
*{{cite journal | author=Weir MR, Dzau VJ |title=The renin-angiotensin-aldosterone system: a specific target for hypertension management |journal=Am. J. Hypertens. |volume=12 |issue= 12 Pt 3 |pages= 205S–213S |year= 2000 |pmid= 10619573 |doi=10.1016/S0895-7061(99)00103-X }}
[[Categoria:Rene]]
 
[[Categoria:Endocrinologia]]
*{{cite journal | author=Berry C, Touyz R, Dominiczak AF, ''et al.'' |title=Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide |journal=Am. J. Physiol. Heart Circ. Physiol. |volume=281 |issue= 6 |pages= H2337–65 |year= 2002 |pmid= 11709400 |doi= }}
 
[[Categoria:Fisiologia]]
*{{cite journal | author=Sernia C |title=A critical appraisal of the intrinsic pancreatic angiotensin-generating system |journal=JOP |volume=2 |issue= 1 |pages= 50–5 |year= 2002 |pmid= 11862023 |doi= }}
 
*{{cite journal | author=Varagic J, Frohlich ED |title=Local cardiac renin-angiotensin system: hypertension and cardiac failure |journal=J. Mol. Cell. Cardiol. |volume=34 |issue= 11 |pages= 1435–42 |year= 2003 |pmid= 12431442 |doi=10.1006/jmcc.2002.2075 }}
 
*{{cite journal | author=Wolf G |title=Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis |journal=Antioxid. Redox Signal. |volume=7 |issue= 9-10 |pages= 1337–45 |year= 2006 |pmid= 16115039 |doi= 10.1089/ars.2005.7.1337 }}
 
*{{cite journal | author=Cazaubon S, Deshayes F, Couraud PO, Nahmias C |title=[Endothelin-1, angiotensin II and cancer] |journal=Med Sci (Paris) |volume=22 |issue= 4 |pages= 416–22 |year= 2006 |pmid= 16597412 |doi= }}
 
*{{cite journal | author=Ariza AC, Bobadilla NA, Halhali A |title=[Endothelin 1 and angiotensin II in preeeclampsia] |journal=Rev. Invest. Clin. |volume=59 |issue= 1 |pages= 48–56 |year= 2007 |pmid= 17569300 |doi= }}
 
}}
 
{{refend}}
 
...
 
==External links==
 
* The [[MEROPS]] online database for peptidases and their inhibitors: [http://merops.sanger.ac.uk/cgi-bin/merops.cgi?id=I04.953 I04.953]
 
* {{MeshName|Angiotensins}}
 
{{Cardiovascular physiology}}
 
{{Neuropeptides}}
 
{{Autacoids}}
 
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
 
{{PBB_Controls
 
| update_page = yes
 
| require_manual_inspection = no
 
| update_protein_box = yes
 
| update_summary = no
 
| update_citations = yes
 
}}
<!--
[[Category:Peptide hormones]]
 
[[Category:Cardiovascular system]]
 
[[Category:Endocrinology]]
 
[[Category:Physiology]]
-->
[[ca:Angiotensina]]
 
Riga 216 ⟶ 111:
 
[[dv:އެންޖީއޯޓެންސިން]]
[[en:angiotensin]]
 
[[fa:آنژیوتانسین دو]]
Riga 222 ⟶ 118:
 
[[id:Angiotensin]]
 
[[it:Angiotensina II]]
 
[[he:אנגיוטנסין]]